TABLE 5.
Potential vaccine candidates for SARS‐CoV‐2 that are under different stages of clinical trials
| Technology | Vaccine | Status of trial | Sponsor/collaborators | NCT number |
|---|---|---|---|---|
| D NA‐based vaccine | INO‐4800 | Phase 1 | Inovio Pharmaceuticals | NCT04336410 |
| bacTRL‐Spike | Phase 2 | Symvivo Corporation, University of British Columbia, Dalhousie University | NCT04334980 | |
| Inactivated virus | CoronaVac (SARS‐CoV‐2 inactivated vaccine) | Phase 1/2 | Sinovac Biotech Co. | NCT04352608, NCT04383574 |
| V‐SARS | Phase 1/2 | Immunitor LLC | NCT04380532 | |
| Modified APC | LV‐SMENP‐DC | Phase 1/2 | Shenzhen Geno‐Immune Medical Institute | NCT04276896 |
| AV‐COVID‐19 | Phase 1/2 | Aivita Biomedical, Inc. | NCT04386252 | |
| Covid‐19/aAPC vaccine | Phase 1 | Shenzhen Geno‐Immune Medical Institute | NCT04299724 | |
| Nonreplicating viral vector | AZD1222 (ChAdOx1 nCoV‐19) | Phase 1/2/3 | Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford | NCT04324606, EudraCT 2020–001072‐15, EudraCT 2020–001228‐32 |
| Ad5‐nCoV | Phase 1/2 | CanSino Biologics Inc., Institute of Biotechnology and so on | NCT04313127, NCT04341389, NCT04398147, ChiCTR2000031781, ChiCTR2000030906 | |
| Protein subunit | NVX‐CoV2373 (SARS‐CoV‐2 rS) | Phase 1 | Novavax | NCT04368988 |
| SCB‐2019 | Phase 1 | Clover Biopharmaceuticals | NCT04405908 | |
| RNA‐based vaccine | BNT162 | Phase 1/2 | Biontech RNA Pharmaceuticals GmbH, Pfizer | NCT04380701, NCT04368728, EudraCT 2020‐001038‐36 |
| mRNA‐1273 | Phase 1 | Moderna, NIAID | NCT04283461 | |
| Repurposed vaccine | Bacille Calmette‐Guerin (BCG) vaccine | Phase 3/4 | University Medical Center Utrecht, Radboud University and so on | NCT04328441, NCT04350931, NCT04362124, NCT04379336, NCT04347876, NCT04327206, NCT04369794, NCT04373291, NCT04384549, NCT04348370, NCT04384614, NCT04387409 |
| Measles‐mumps‐rubella (MMR) vaccine | Phase 3 | Kasr El Aini Hospital | NCT04357028 |